ClearPoint Neuro, Inc.
| NASDAQ: CLPT | Healthcare / Medical Devices & Instruments / USA |
| 8.22 | +0.3700 | +4.71% | Vol 25.57K | 1Y Perf -18.65% |
| Mar 22nd, 2023 14:36 DELAYED |
| BID | 8.18 | ASK | 8.26 | ||
| Open | 7.95 | Previous Close | 7.85 | ||
| Pre-Market | 7.90 | After-Market | - | ||
| 0.05 0.64% | - - |
| Target Price | 18.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 124.24 | Finscreener Ranking | ★★★★+ 55.41 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★+ 47.95 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★★ 50.50 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 12.25 | Earnings Rating | — | |
| Market Cap | 202.29M | Earnings Date | 10th May 2023 | |
| Alpha | 0.03 | Standard Deviation | 0.21 | |
| Beta | 1.08 |
Today's Price Range 7.748.34 | 52W Range 7.0016.96 | 5 Year PE Ratio Range -24.80-2.40 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 3.15% | ||
| 1 Month | -8.19% | ||
| 3 Months | -2.00% | ||
| 6 Months | -22.35% | ||
| 1 Year | -18.65% | ||
| 3 Years | 135.74% | ||
| 5 Years | 166.10% | ||
| 10 Years | -85.88% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -69.76 | |||
ROE last 12 Months | -38.57 | |||
ROA (5Y Avg) | -7.86 | |||
ROA last 12 Months | -25.62 | |||
ROC (5Y Avg) | -55.21 | |||
ROC last 12 Months | -27.33 | |||
Return on invested Capital Q | -7.16 | |||
Return on invested Capital Y | -6.36 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -12.10 | ||||
| 5.14 | ||||
| 13.45 | ||||
| - | ||||
| -14.60 | ||||
| -0.71 | ||||
| 5.25 | ||||
| 1.62 | ||||
| 176.28M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.20 | ||||
| 8.80 | ||||
| 0.22 | ||||
| 0.30 | ||||
| -48.20 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 69.00 | ||||
| -80.70 | ||||
| -76.60 | ||||
| -76.00 | ||||
| -78.36 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 15.38M | ||||
| 0.63 | ||||
| 22.25 | ||||
| 21.19 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | -0.22 | -0.18 | 18.18 |
| Q03 2022 | -0.19 | -0.15 | 21.05 |
| Q02 2022 | -0.18 | -0.18 | 0.00 |
| Q01 2022 | -0.20 | -0.17 | 15.00 |
| Q04 2021 | - | -0.19 | - |
| Q03 2021 | - | -0.18 | - |
| Q02 2021 | -0.14 | -0.17 | -21.43 |
| Q01 2021 | -0.15 | -0.13 | 13.33 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 10th May 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 25.57K |
| Shares Outstanding | 24.61K |
| Shares Float | 21.91M |
| Trades Count | 621 |
| Dollar Volume | 208.15K |
| Avg. Volume | 70.89K |
| Avg. Weekly Volume | 67.00K |
| Avg. Monthly Volume | 73.38K |
| Avg. Quarterly Volume | 72.28K |
ClearPoint Neuro, Inc. (NASDAQ: CLPT) stock closed at 7.85 per share at the end of the most recent trading day (a 7.09% change compared to the prior day closing price) with a volume of 45.61K shares and market capitalization of 202.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 38 people. ClearPoint Neuro, Inc. CEO is Joseph M. Burnett.
The one-year performance of ClearPoint Neuro, Inc. stock is -18.65%, while year-to-date (YTD) performance is -7.32%. CLPT stock has a five-year performance of 166.1%. Its 52-week range is between 7 and 16.96, which gives CLPT stock a 52-week price range ratio of 12.25%
ClearPoint Neuro, Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 5.14, a price-to-sale (PS) ratio of 13.45, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.62%, a ROC of -27.33% and a ROE of -38.57%. The company’s profit margin is -78.36%, its EBITDA margin is -76.60%, and its revenue ttm is $15.38 Million , which makes it $0.63 revenue per share.
Of the last four earnings reports from ClearPoint Neuro, Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. ClearPoint Neuro, Inc.’s next earnings report date is 10th May 2023.
The consensus rating of Wall Street analysts for ClearPoint Neuro, Inc. is Strong Buy (1), with a target price of $18.5, which is +124.24% compared to the current price. The earnings rating for ClearPoint Neuro, Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ClearPoint Neuro, Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ClearPoint Neuro, Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 33.69, ATR14 : 0.49, CCI20 : -76.18, Chaikin Money Flow : -0.19, MACD : -0.37, Money Flow Index : 18.06, ROC : -5.65, RSI : 43.61, STOCH (14,3) : 35.26, STOCH RSI : 1.00, UO : 42.76, Williams %R : -64.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ClearPoint Neuro, Inc. in the last 12-months were: Joseph M. Burnett (Sold 18 867 shares of value $303 193 )
ClearPoint Neuro, Inc.
MRI Interventions Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. It has two product platforms: ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace system, which is under development, to be used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint Neuro Intervention System and The ClearTrace Cardiac Intervention System.
CEO: Joseph M. Burnett
Telephone: +1 949 900-6833
Address: 5 Musick, Irvine 92618, CA, US
Number of employees: 38
TipRanks News for CLPT
Thu, 16 Feb 2023 12:30 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Community Health (CYH), ClearPoint Neuro (CLPT) and Jasper Therapeutics (JSPR)
- TipRanks. All rights reserved.
